“The rules of the past no longer apply.” – Ken Anderson, MD, Dana Farber
An interview with Ken Anderson at the 53rd ASH Conference on New Therapies and Changing Cytogenetics, that might be of some interest and value to those of you with abnormalities that were once considered problematic that are no longer. It is becoming a trend to embrace the findings of researchers out of UAMS that Gene Expression Profiling (GEP) is a valid and helpful diagnostic tool in the treatment of multiple myeloma. In past presentations I have posted, this acceptance of it’s value has yet to get pushed into the clinical setting at local oncology centers. It is still relegated to only the largest of research facilities. If you have any of these issues expressed from a general oncologist/hematologist, you might want to consider a consultation at a larger research facility for more in depth testing of your genetic presentation to see if your treatment protocol needs to be adjusted for a better outcome.
